Revolutionizing treatments for chronic inflammation.
Our approach to disease therapy
We target chronic inflammatory and auto immune conditions using a biological molecule to decrease leukocyte driven inflammation.
Alzheimer’s Disease
Chronic inflammation is increasingly recognized as a key contributor to Alzheimer’s disease progression, influencing synaptic dysfunction, vascular health, and neurodegeneration. Dysregulated Reelin signaling has been implicated in neuroinflammatory amplification, endothelial dysfunction, and impaired tissue homeostasis.
Multiple Sclerosis
Multiple Sclerosis is characterized by chronic immune-mediated inflammation, blood–brain barrier dysfunction, and progressive neurological damage. Emerging evidence suggests that Reelin contributes to immune cell trafficking, endothelial activation, and sustained inflammatory signaling that exacerbate CNS pathology.
Rheumatoid Arthritis
Rheumatoid Arthritis is a chronic autoimmune disease marked by persistent synovial inflammation, immune cell infiltration, and progressive joint damage. Reelin expression has been observed in inflamed peripheral tissues, suggesting a role in sustaining immune activation and tissue-level inflammation.
Modulation of immune responses by targeting peripheral Reelin
Chronic inflammation underlies a wide range of human diseases, yet existing anti-inflammatory therapies often compromise immune function or lose effectiveness over time. At Reelin Therapeutics, we are pioneering a fundamentally different strategy: modulating Reelin levels in the plasma to restore immune balance without broad immunosuppression or compromising CNS function.
